Timing Protocol
Expert-analyzed timing recommendations for glp-1 agonists based on what 5 longevity researchers say about when, how, and what to take it with.
Quick Timing Guide
Once-weekly injection. No specific time-of-day requirement. Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia).
Moderate Consensus
on GLP-1 Agonists overall
Timing
Once-weekly injection. No specific time-of-day requirement. Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia).
Dosage
Semaglutide: typically starts at 0.25mg/week, titrated up to 2.4mg/week for weight management. Tirzepatide: starts at 2.5mg/week, titrated up to 15mg/week. Dosing is individualized by a prescribing physician (Attia).
Form
Injectable (subcutaneous, once weekly). Oral formulations are in development. Some clinicians use compounded peptide formulations at lower doses (Attia, Koniver).
Notes
This is a prescription medication — not a supplement. Requires physician oversight, regular monitoring via DEXA scans for body composition, and blood work. Compounded versions from reputable pharmacies may offer lower-dose options. High cost remains a significant barrier to access (Attia). Hyman strongly advocates addressing diet and lifestyle first before considering pharmaceutical intervention.
Huberman covers GLP-1 agonists across multiple contexts: hunger neuroscience, peptide therapy, and fat loss protocols. He features Dr. Zachary Knight (UCSF) explaining the mechanism of GLP-1 drugs, their origin from Gila monster venom, and the evolution from short-acting to long-acting forms. He discusses how GLP-1 acts on brain stem and hypothalamic circuits to suppress appetite. In peptide therapy episodes, Dr. Craig Koniver discusses micro-dosing semaglutide and tirzepatide to mitigate side effects. Huberman also frequently mentions yerba mate as a natural GLP-1 stimulator for fat loss.
Go beyond the consensus — see exactly what each expert says about glp-1 agonists.